摘要
目的:探讨热毒宁联合头孢哌酮舒巴坦钠对多重耐药菌呼吸道感染患儿临床疗效及安全性。方法:选择65例多重耐药菌呼吸道感染患儿进行随机分组对照研究,对照组32例患儿予头孢哌酮舒巴坦静点治疗,治疗组33例患儿在此基础上予热毒宁注射液辅助治疗,3 d为1个疗程,两组患儿均治疗1个疗程。通过比较治疗前后两组患儿临床症状变化以及治疗后的总有效率和TESS评分来探究热毒宁联合头孢哌酮舒巴坦钠对多重耐药菌呼吸道感染患儿临床疗效及安全性。结果:治疗前,两组患儿发热症状评分比较差异无统计学意义(P>0.05);治疗后,两组患儿的发热症状评分均降低(P<0.05),其中治疗组评分比对照组低(P<0.05)。治疗前,两组患儿流涕症状评分比较差异无统计学意义(P>0.05);治疗后,两组患儿的流涕症状评分均降低(P<0.05),其中治疗组评分比对照组低(P<0.05)。治疗前,两组患儿咳嗽症状评分比较差异无统计学意义(P>0.05);治疗后,两组患儿的咳嗽症状评分均降低(P<0.05),其中治疗组评分比对照组低(P<0.05)。治疗3 d后,对照组治愈11例(34.38%),好转13例(40.63%),无效8例(25.00%),总有效率为75.00%;治疗组治愈18(56.25%)例好转14(42.42%)无效1(3.03%),总有效率为90.91%。治疗组的治疗有效率比对照组较高(P<0.05)。在治疗1 d时,对照组TESS评分为1.23±0.17,治疗组TESS评分为1.25±0.15,两组之间无明显差异(P>0.05);治疗3 d时对照组TESS评分为1.32±0.18,治疗组TESS评分为1.34±0.19,两组TESS评分无明显差异(P>0.05)。结论:热毒宁联合头孢哌酮舒巴坦钠对多重耐药菌呼吸道感染患儿的治疗有良好的临床疗效而且及安全性较好。
Objective： To investigate the efficacy and safety of Reduning Injection combined with Cefoperazone Sulbactam Sodium in treatment of multiple drug resistant bacteria in children with respiratory tract infection. Methods ： 65 cases of multi drug resistant bacteria in children with respiratory tract infection were selected and randomly divided into 2 groups. 32 cases in the control group were treated with Cefoperazone Sulbactam Sodium, 33 cases in the treatment group were treated on the base of the control group with Reduning Injection. 3 days for a course and patients were treated for l course. By comparing the treatment before and after the children before and after treatment of two groups of children with changes in clinical symptoms and treatment after the total efficiency and Tess score to explore Reduning combined with cefoperazone sulbactam on multiple drug - resistant bacteria in respiratory tract infection clinical efficacy and safety of children. Results ： Before treatment, the difference between the two groups of children with fever symptoms score, had no sta- tistical significance （ P 〉 0. 05 ） ; after treatment, fever symptom scores in the two groups of children were decreased （ P 〈 0, 05）, fever symptom scores in the treatment group was lower than the control group （ P 〈 0.05 ）. Before treat- ment, the difference between the two groups of children with rhinorrhoea symptoms score bad no statistical significance （ P 〉 0.05 ） ; after treatment, runny nose symptom scores in the two groups of children were decreased （ P 〈 0. 05 ）. The runny nose symptom scores in the treatment group was lower than the control group （ P 〈 0. 05 ）. Before treatment, the two groups of children with cough symptom score in two groups had no significance difference （ P 〉 0.05 ） ; after treatment, two groups of children with cough symptom scores were lower （ P 〈 0. 05 ）, cough symptom scores in the treatment group was lower than the control group （P 〈 0.05 ）. After 3 days of treatment, the control group cured 11 cases （34. 38% ） , improvement 13 cases （40.63%）, ineffective 8 cases （25.00%）, the total effective rate was 75.00%. The treatment group cure 18 （56.25%） , improved 14 （42.42%） and 1 ineffective （5.03%）, and the total effective rate was 90. 91%. The effective rate of treatment group was higher than the control group （ P 〈 0. 05 ）. In the treatment of 1 days,TESS score in the control group was 1.23 ± 0.17, and TESS score in the treatment group was 1.34 ±0.19 （ P 〉 0. 05） ; In 3 days of treatment, the TESS score in the control group was 1.32 ± 0.18, the TESS score in the treatment group was 1.34 ± 0.19（P 〉 0. 05 ）. Conclusion： Reduning combined with cefoperazone sulbactam on multiple drug -resistant bacteria in respiratory tract infection patients had good clinical efficacy and good safety.
出处
《中华中医药学刊》
CAS
北大核心
2017年第3期677-679,共3页
Chinese Archives of Traditional Chinese Medicine
基金
河南省创新型科技人才队伍建设工程基金项目(2014GG032)
关键词
热毒宁注射液
头孢哌酮舒巴坦钠
多重耐药菌
呼吸道感染
临床疗效
安全性
Reduning injection
cefoperazone sulbactam sodium
multi drug resistant bacteria
respiratory tract in-fection
clinical efficacy
safety
